Indian pharmaceutical companies are preparing to launch generic versions of Novo Nordisk's weight-loss drug, semaglutide, potentially reducing its price by up to 80%.

Ascletis completes enrollment in US phase IIa study of small molecule oral GLP-1R agonist, ASC30 to treat obesity: Hong Kong Wednesday, August 6, 2025, 10:00 Hrs [IST] Ascletis Ph ...

The Milwaukee Bucks Health and Wellness program is celebrating its one-year anniversary. The free medical program was ...

Linda Yaccarino, the former X CEO who left the social media company in the wake of yet another Elon Musk controversy, has ...

The post, at the company that focuses on care for GLP-1 users, comes after Yaccarino left Elon Musk's X in July.

A new drug that skips neurons and targets support cells cut weight and improved insulin response in lab animals, without ...

Lawsuits from at least 26 patients have been filed in Marion County against Eli Lilly and Co. for its marketing of the drugs ...

Linda Yaccarino, the former CEO of Elon Musk's social media platform X, announced she had a new job on Tuesday -- but her ...

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

Ali Eastburn missed her son’s rehearsal dinner — and nearly missed the wedding — when her appendix burst while traveling, ...

For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with ...

Welcome to Contract Pharma’s annual ranking of the Top 20 Pharma and Biopharma Companies, based on fiscal year 2024 ...